Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 4/2015

01.12.2015 | Original Research

Aggressive Surgical Approach for Gallbladder Cancer: a Single-Center Experience from Northern India

verfasst von: Santosh Kumar Singh, Rajnish Talwar, Narayanan Kannan, Arvind Kumar Tyagi, Pradeep Jaiswal, Adarsh Kumar

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Gallbladder cancer (GBC) is an aggressive disease with dismal results of surgical treatment mainly because of advanced stage at presentation. The objective of this study was to investigate whether aggressive surgical treatment can be associated with reasonable survival for patients with GBC at acceptable morbidity and mortality.

Methods

A total of 113 patients with proven or presumptive diagnosis of GBC were recruited prospectively over a period of 2 years and evaluated for diagnosis and staging by appropriate investigations. Seven out of 113 patients were found to have benign pathology either intraoperatively or on histopathological examination hence excluded from follow-up and survival analysis. Out of 32 potentially resectable patients, only 21 patients could finally be resected with curative intent. Patients found unresectable/metastatic disease intraoperatively (n = 11) were treated with palliative chemotherapy if eligible for the same. Short-term morbidity, perioperative mortality, disease-free survival (DFS), and median overall survival (OS) of surgically resected patients were analyzed. Median OS of resected patients was compared with that of unresectable patients.

Results

Overall resectability rate in this study cohort was 19.8 % (21/106). Overall mortality was 4.7 % and morbidity was 42.8 %. Stage distribution of resected patients was as follows: stage II (3), stage IIIA (9), stage IIIB (8), and stage IVA (1). DFS at 12 and 18 months was found to be 82.5 and 73.3 %, respectively. Mean DFS was 19.9 months (SE 1.42, 95 % CI). Mean OS for resected patients was 21 months and that for unresectable patients was 11.3 months only. Both groups were compared using log rank (Mantel-cox) test and statistically significant difference in OS was observed (p value <0.0001).

Conclusion

Since curative resection is the only chance of cure, aggressive surgical approach adopted by us is justified with acceptable mortality and morbidity and encouraging overall survival.
Literatur
1.
Zurück zum Zitat Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet. 1978;147:929–42.PubMed Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. Surg Gynecol Obstet. 1978;147:929–42.PubMed
2.
Zurück zum Zitat Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder: results of the French Surgical Association Survey. Ann Surg. 1994;219:275–80.PubMedCentralCrossRefPubMed Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder: results of the French Surgical Association Survey. Ann Surg. 1994;219:275–80.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Wilkinson DS. Carcinoma of the gall-bladder: an experience and review of the literature. Aust N Z J Surg. 1995;65:724–7.CrossRefPubMed Wilkinson DS. Carcinoma of the gall-bladder: an experience and review of the literature. Aust N Z J Surg. 1995;65:724–7.CrossRefPubMed
4.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.PubMedCentralCrossRefPubMed Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–18.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406.PubMedCentralCrossRefPubMed Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236:397–406.PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Taylor M, Forster J, Langer B, et al. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg. 1997;173:467–71.CrossRefPubMed Taylor M, Forster J, Langer B, et al. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg. 1997;173:467–71.CrossRefPubMed
7.
Zurück zum Zitat Bartlett DL, Fong Y, Fortner JG, et al. Long-term results after resection for gallbladder cancer: implications for staging and management. Ann Surg. 1996;224:639–46.PubMedCentralCrossRefPubMed Bartlett DL, Fong Y, Fortner JG, et al. Long-term results after resection for gallbladder cancer: implications for staging and management. Ann Surg. 1996;224:639–46.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Kondo S, Nimura Y, Hayakawa N, et al. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg. 2000;87:418–22.CrossRefPubMed Kondo S, Nimura Y, Hayakawa N, et al. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg. 2000;87:418–22.CrossRefPubMed
9.
Zurück zum Zitat Kondo S, Nimura Y, Hayakawa N, et al. Extensive surgery for carcinoma of the gallbladder. Br J Surg. 2002;89:179–84.CrossRefPubMed Kondo S, Nimura Y, Hayakawa N, et al. Extensive surgery for carcinoma of the gallbladder. Br J Surg. 2002;89:179–84.CrossRefPubMed
10.
Zurück zum Zitat Kondo S, Nimura Y, Kamiya J, et al. Mode of tumor spread and surgical strategy in gallbladder carcinoma. Langenbecks Arch Surg. 2002;387:222–8.CrossRefPubMed Kondo S, Nimura Y, Kamiya J, et al. Mode of tumor spread and surgical strategy in gallbladder carcinoma. Langenbecks Arch Surg. 2002;387:222–8.CrossRefPubMed
11.
Zurück zum Zitat Kondo S, Nimura Y, Kamiya J, et al. Five-year survivors after aggressive surgery for stage IV gallbladder cancer. J Hepatobiliary Pancreat Surg. 2001;8:511–7.CrossRefPubMed Kondo S, Nimura Y, Kamiya J, et al. Five-year survivors after aggressive surgery for stage IV gallbladder cancer. J Hepatobiliary Pancreat Surg. 2001;8:511–7.CrossRefPubMed
12.
Zurück zum Zitat Shirai Y, Ohtani T, Tsukada K, et al. Radical surgery is justified for locally advanced gallbladder carcinoma if complete resection is feasible. Am J Gastroenterol. 1997;92:181–2.PubMed Shirai Y, Ohtani T, Tsukada K, et al. Radical surgery is justified for locally advanced gallbladder carcinoma if complete resection is feasible. Am J Gastroenterol. 1997;92:181–2.PubMed
13.
Zurück zum Zitat Shirai Y, Ohtani T, Tsukada K, et al. Pancreaticoduodenectomy for gallbladder cancer with peripancreatic nodal metastases. Hepatogastroenterology. 1997;44:376–7.PubMed Shirai Y, Ohtani T, Tsukada K, et al. Pancreaticoduodenectomy for gallbladder cancer with peripancreatic nodal metastases. Hepatogastroenterology. 1997;44:376–7.PubMed
14.
Zurück zum Zitat Shirai Y, Ohtani T, Tsukada K, et al. Combined pancreaticoduodenectomy and hepatectomy for patients with locally advanced gallbladder carcinoma: long term results. Cancer. 1997;80:1904–9.CrossRefPubMed Shirai Y, Ohtani T, Tsukada K, et al. Combined pancreaticoduodenectomy and hepatectomy for patients with locally advanced gallbladder carcinoma: long term results. Cancer. 1997;80:1904–9.CrossRefPubMed
16.
Zurück zum Zitat Todoroki T, Kawamoto T, Takahashi H, et al. Treatment of gallbladder cancer by radical resection. Br J Surg. 1999;86:622–7.CrossRefPubMed Todoroki T, Kawamoto T, Takahashi H, et al. Treatment of gallbladder cancer by radical resection. Br J Surg. 1999;86:622–7.CrossRefPubMed
17.
Zurück zum Zitat Todoroki T, Takahashi H, Koike N, et al. Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival. Hepatogastroenterology. 1999;46:2114–21.PubMed Todoroki T, Takahashi H, Koike N, et al. Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival. Hepatogastroenterology. 1999;46:2114–21.PubMed
18.
Zurück zum Zitat Doty JR, Cameron JL, Yeo CJ, et al. Cholecystectomy, liver resection, and pylorus-preserving pancreaticoduodenectomy for gallbladder cancer: report of five cases. J Gastrointest Surg. 2002;6:776–80.CrossRefPubMed Doty JR, Cameron JL, Yeo CJ, et al. Cholecystectomy, liver resection, and pylorus-preserving pancreaticoduodenectomy for gallbladder cancer: report of five cases. J Gastrointest Surg. 2002;6:776–80.CrossRefPubMed
19.
Zurück zum Zitat Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000;232:557–69.PubMedCentralCrossRefPubMed Fong Y, Jarnagin W, Blumgart LH. Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention. Ann Surg. 2000;232:557–69.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Nishio H, Nagino M, Ebata T, Yokoyama Y, Tsuyoshi I, Yuji N. Aggressive surgery for stage IV gallbladder carcinoma; what are the contraindications? J Hepatobiliary Pancreat Surg. 2007;14:351–7.CrossRefPubMed Nishio H, Nagino M, Ebata T, Yokoyama Y, Tsuyoshi I, Yuji N. Aggressive surgery for stage IV gallbladder carcinoma; what are the contraindications? J Hepatobiliary Pancreat Surg. 2007;14:351–7.CrossRefPubMed
21.
Zurück zum Zitat Yokomizo H, Yamane T, Hirata T, et al. Surgical treatment of pT2 gallbladder carcinoma: a reevaluation of the therapeutic effect of hepatectomy and extrahepatic bile duct resection based on the long-term outcome. Ann Surg Oncol. 2007;14:1366–73.CrossRefPubMed Yokomizo H, Yamane T, Hirata T, et al. Surgical treatment of pT2 gallbladder carcinoma: a reevaluation of the therapeutic effect of hepatectomy and extrahepatic bile duct resection based on the long-term outcome. Ann Surg Oncol. 2007;14:1366–73.CrossRefPubMed
22.
Zurück zum Zitat Nair CK, Kothari KC. Role of diagnostic laparoscopy in assessing operability in borderline resectable gastrointestinal cancers. J Min Access Surg. 2012;8:45–9.CrossRef Nair CK, Kothari KC. Role of diagnostic laparoscopy in assessing operability in borderline resectable gastrointestinal cancers. J Min Access Surg. 2012;8:45–9.CrossRef
23.
Zurück zum Zitat Agarwal AK, Kalayarasan R, Javed A, et al. The role of staging laparoscopy in primary gall bladder cancer—an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. Ann Surg. 2013;258(2):318–23.CrossRefPubMed Agarwal AK, Kalayarasan R, Javed A, et al. The role of staging laparoscopy in primary gall bladder cancer—an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer. Ann Surg. 2013;258(2):318–23.CrossRefPubMed
24.
Zurück zum Zitat Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4:167–76.CrossRefPubMed Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4:167–76.CrossRefPubMed
25.
Zurück zum Zitat Tsukada K, Kurosaki I, Uchida K, et al. Lymph node spread from carcinoma of the gallbladder. Cancer. 1997;80:661–7.CrossRefPubMed Tsukada K, Kurosaki I, Uchida K, et al. Lymph node spread from carcinoma of the gallbladder. Cancer. 1997;80:661–7.CrossRefPubMed
26.
Zurück zum Zitat Shimada H, Endo I, Togo S, Nakano A, Izumi T, Nakagawara G. The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer. 1997;79:892–9.CrossRefPubMed Shimada H, Endo I, Togo S, Nakano A, Izumi T, Nakagawara G. The role of lymph node dissection in the treatment of gallbladder carcinoma. Cancer. 1997;79:892–9.CrossRefPubMed
27.
Zurück zum Zitat Yoshio S, Toshifumi W, Jun S, Katsuyoshi H. Regional lymphadenectomy for gallbladder cancer: rational extent, technical details, and patient outcomes. World J Gastroenterol. 2012;18(22):2775–83. June 14.CrossRef Yoshio S, Toshifumi W, Jun S, Katsuyoshi H. Regional lymphadenectomy for gallbladder cancer: rational extent, technical details, and patient outcomes. World J Gastroenterol. 2012;18(22):2775–83. June 14.CrossRef
28.
Zurück zum Zitat Shukla PJ, Barreto G, Kakade A, Shrikhande SV. Revision surgery for incidental gallbladder cancer: factors influencing operability and further evidence for T1b tumors. HPB (Oxford). 2008;10:43–7.CrossRef Shukla PJ, Barreto G, Kakade A, Shrikhande SV. Revision surgery for incidental gallbladder cancer: factors influencing operability and further evidence for T1b tumors. HPB (Oxford). 2008;10:43–7.CrossRef
29.
Zurück zum Zitat D’Angelica M, Dalal KM, et al. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16(4):806–16.CrossRefPubMed D’Angelica M, Dalal KM, et al. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16(4):806–16.CrossRefPubMed
30.
Zurück zum Zitat Shirai Y, Ohtani T, Tsukada K, Hatakeyama K. Combined pancreaticoduodenectomy and hepatectomy for patients with locally advanced gallbladder carcinoma. Long Term Results Cancer. 1997;80:1904–9.PubMed Shirai Y, Ohtani T, Tsukada K, Hatakeyama K. Combined pancreaticoduodenectomy and hepatectomy for patients with locally advanced gallbladder carcinoma. Long Term Results Cancer. 1997;80:1904–9.PubMed
31.
Zurück zum Zitat Shimizu Y, Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, et al. Should the extrahepatic bile duct be resected for locally advanced gallbladder cancer? Surgery. 2004;136:1012–7.CrossRefPubMed Shimizu Y, Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, et al. Should the extrahepatic bile duct be resected for locally advanced gallbladder cancer? Surgery. 2004;136:1012–7.CrossRefPubMed
32.
Zurück zum Zitat Giuliante F, Ardito F, Vellone M, Clemente G, Nuzzo G. Port-sites excision for gallbladder cancer incidentally found after laparoscopic cholecystectomy. Am J Surg. 2006;191:114–6.CrossRefPubMed Giuliante F, Ardito F, Vellone M, Clemente G, Nuzzo G. Port-sites excision for gallbladder cancer incidentally found after laparoscopic cholecystectomy. Am J Surg. 2006;191:114–6.CrossRefPubMed
33.
Zurück zum Zitat DeVita, Hellman and Rosenberg. Principles and practice of oncology.9th Edition. Lippincott Williams & Wilkins 2011: Table 85.17. DeVita, Hellman and Rosenberg. Principles and practice of oncology.9th Edition. Lippincott Williams & Wilkins 2011: Table 85.17.
34.
Zurück zum Zitat Tsukada K, Hatakamaya K, Kurosaki I, et al. Outcome of radical surgery for carcinoma of the gallbladder according to TNM stage. Surgery. 1996;120:816–20.CrossRefPubMed Tsukada K, Hatakamaya K, Kurosaki I, et al. Outcome of radical surgery for carcinoma of the gallbladder according to TNM stage. Surgery. 1996;120:816–20.CrossRefPubMed
Metadaten
Titel
Aggressive Surgical Approach for Gallbladder Cancer: a Single-Center Experience from Northern India
verfasst von
Santosh Kumar Singh
Rajnish Talwar
Narayanan Kannan
Arvind Kumar Tyagi
Pradeep Jaiswal
Adarsh Kumar
Publikationsdatum
01.12.2015
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 4/2015
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-015-9766-4

Weitere Artikel der Ausgabe 4/2015

Journal of Gastrointestinal Cancer 4/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.